Repurposing Antimalarial Pyronaridine as a DNA Repair Inhibitor to Exploit the Full Potential of Gold-Nanoparticle-Mediated Radiation Response

Author:

Jackson Nolan,Alhussan AbdulazizORCID,Bromma KyleORCID,Jay David,Donnelly James C.,West Frederick G.ORCID,Lavasanifar Afsaneh,Weinfeld Michael,Beckham Wayne,Chithrani Devika B.ORCID

Abstract

Radiation therapy (RT) is frequently used to locally treat tumors. One of the major issues in RT is normal tissue toxicity; thus, it is necessary to limit dose escalation for enhanced local control in patients that have locally advanced tumors. Integrating radiosensitizing agents such as gold nanoparticles (GNPs) into RT has been shown to greatly increase the cure rate of solid tumors. The objective of this study was to explore the repurposing of an antimalarial drug, pyronaridine (PYD), as a DNA repair inhibitor to further enhance RT/GNP-induced DNA damage in cancerous cell lines. We were able to achieve inhibitory effects of DNA repair due to PYD at 500 nM concentration. Our results show a significant enhancement in DNA double-strand breaks of 42% in HeLa cells treated with PYD/GNP/RT in comparison to GNP/RT alone when irradiated with a dose of 2 Gy. Furthermore, there was a significant reduction in cellular proliferation for both HeLa and HCT-116 irradiated cells with the combined treatment of PYD/GNP/RT. Therefore, the emergence of promising novel concepts introduced in this study could lay the foundation for the transition of this treatment modality into clinical environments.

Funder

Nanomedicines Innovation Network

Natural Sciences and Engineering Research Council

Kuwait Foundation for the Advancement of Sciences

Canadian Institute for Health Research

Alberta Cancer Foundation Transformative Program Project

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference77 articles.

1. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics;Cronin;Cancer,2018

2. Canadian Cancer Statistics Advisory Committee in Collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada (2022, October 15). Canadian Cancer Statistics. Available online: https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2021-statistics/2021-pdf-en-final.pdf.

3. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

4. Cancer and Radiation Therapy: Current Advances and Future Directions;Baskar;Int. J. Med Sci.,2012

5. The role of radiotherapy in cancer treatment—Estimating optimal utilization from a review of evidence-based clinical guidelines;Delaney;Cancer,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3